vs
Side-by-side financial comparison of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) and UNITED NATURAL FOODS INC (UNFI). Click either name above to swap in a different company.
UNITED NATURAL FOODS INC is the larger business by last-quarter revenue ($7.8B vs $4.7B, roughly 1.7× TEVA PHARMACEUTICAL INDUSTRIES LTD). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs -0.1%, a 10.3% gap on every dollar of revenue. On growth, TEVA PHARMACEUTICAL INDUSTRIES LTD posted the faster year-over-year revenue change (11.4% vs -0.4%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $-54.0M). Over the past eight quarters, TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue compounded faster (11.1% CAGR vs 0.4%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
United Natural Foods, Inc. (UNFI) is a Providence, Rhode Island–based natural and organic food company. The largest publicly traded wholesale distributor of health and specialty food in the United States and Canada, it is Whole Foods Market's main supplier, with their traffic making up over a third of its revenue in 2018.
TEVA vs UNFI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.7B | $7.8B |
| Net Profit | $481.0M | $-4.0M |
| Gross Margin | 56.4% | 13.4% |
| Operating Margin | 6.4% | 0.2% |
| Net Margin | 10.2% | -0.1% |
| Revenue YoY | 11.4% | -0.4% |
| Net Profit YoY | 321.7% | 81.0% |
| EPS (diluted) | $0.42 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.7B | $7.8B | ||
| Q3 25 | $4.5B | $7.7B | ||
| Q2 25 | $4.2B | $8.1B | ||
| Q1 25 | $3.9B | $8.2B | ||
| Q4 24 | $4.2B | $7.9B | ||
| Q3 24 | $4.3B | $8.2B | ||
| Q2 24 | $4.2B | $7.5B | ||
| Q1 24 | $3.8B | $7.8B |
| Q4 25 | $481.0M | $-4.0M | ||
| Q3 25 | $433.0M | $-87.0M | ||
| Q2 25 | $282.0M | $-7.0M | ||
| Q1 25 | $214.0M | $-3.0M | ||
| Q4 24 | $-217.0M | $-21.0M | ||
| Q3 24 | $-437.0M | $-37.0M | ||
| Q2 24 | $-846.0M | $-21.0M | ||
| Q1 24 | $-139.0M | $-15.0M |
| Q4 25 | 56.4% | 13.4% | ||
| Q3 25 | 51.4% | 13.4% | ||
| Q2 25 | 50.3% | 13.4% | ||
| Q1 25 | 48.2% | 13.1% | ||
| Q4 24 | 50.2% | 13.2% | ||
| Q3 24 | 49.6% | 13.7% | ||
| Q2 24 | 48.6% | 13.6% | ||
| Q1 24 | 46.4% | 13.3% |
| Q4 25 | 6.4% | 0.2% | ||
| Q3 25 | 19.7% | -1.0% | ||
| Q2 25 | 10.9% | 0.2% | ||
| Q1 25 | 13.3% | 0.3% | ||
| Q4 24 | -0.7% | 0.1% | ||
| Q3 24 | -1.2% | 0.0% | ||
| Q2 24 | -0.1% | 0.1% | ||
| Q1 24 | -5.7% | 0.2% |
| Q4 25 | 10.2% | -0.1% | ||
| Q3 25 | 9.7% | -1.1% | ||
| Q2 25 | 6.8% | -0.1% | ||
| Q1 25 | 5.5% | -0.0% | ||
| Q4 24 | -5.1% | -0.3% | ||
| Q3 24 | -10.1% | -0.5% | ||
| Q2 24 | -20.3% | -0.3% | ||
| Q1 24 | -3.6% | -0.2% |
| Q4 25 | $0.42 | $-0.06 | ||
| Q3 25 | $0.37 | $-1.43 | ||
| Q2 25 | $0.24 | $-0.12 | ||
| Q1 25 | $0.18 | $-0.05 | ||
| Q4 24 | $-0.19 | $-0.35 | ||
| Q3 24 | $-0.39 | $-0.63 | ||
| Q2 24 | $-0.75 | $-0.34 | ||
| Q1 24 | $-0.12 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6B | $38.0M |
| Total DebtLower is stronger | — | $1.9B |
| Stockholders' EquityBook value | $7.9B | $1.5B |
| Total Assets | $40.7B | $7.6B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6B | $38.0M | ||
| Q3 25 | $2.2B | $44.0M | ||
| Q2 25 | $2.2B | $52.0M | ||
| Q1 25 | $1.7B | $44.0M | ||
| Q4 24 | $3.3B | $37.0M | ||
| Q3 24 | $3.3B | $40.0M | ||
| Q2 24 | $2.3B | $39.0M | ||
| Q1 24 | $3.0B | $34.0M |
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $7.9B | $1.5B | ||
| Q3 25 | $7.3B | $1.6B | ||
| Q2 25 | $6.8B | $1.6B | ||
| Q1 25 | $6.3B | $1.6B | ||
| Q4 24 | $5.4B | $1.6B | ||
| Q3 24 | $6.1B | $1.6B | ||
| Q2 24 | $6.4B | $1.7B | ||
| Q1 24 | $7.3B | $1.7B |
| Q4 25 | $40.7B | $7.6B | ||
| Q3 25 | $39.9B | $7.6B | ||
| Q2 25 | $40.1B | $7.6B | ||
| Q1 25 | $38.4B | $7.7B | ||
| Q4 24 | $39.3B | $8.0B | ||
| Q3 24 | $41.8B | $7.5B | ||
| Q2 24 | $41.3B | $7.6B | ||
| Q1 24 | $42.8B | $7.7B |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 1.21× | ||
| Q1 25 | — | 1.27× | ||
| Q4 24 | — | 1.38× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | — | 1.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2B | $-38.0M |
| Free Cash FlowOCF − Capex | $1.0B | $-54.0M |
| FCF MarginFCF / Revenue | 21.6% | -0.7% |
| Capex IntensityCapex / Revenue | 3.0% | 0.2% |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $344.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $-38.0M | ||
| Q3 25 | $369.0M | $160.0M | ||
| Q2 25 | $227.0M | $173.0M | ||
| Q1 25 | $-105.0M | $247.0M | ||
| Q4 24 | $575.0M | $-110.0M | ||
| Q3 24 | $693.0M | $199.0M | ||
| Q2 24 | $103.0M | $125.0M | ||
| Q1 24 | $-124.0M | $183.0M |
| Q4 25 | $1.0B | $-54.0M | ||
| Q3 25 | $233.0M | $86.0M | ||
| Q2 25 | $131.0M | $119.0M | ||
| Q1 25 | $-232.0M | $193.0M | ||
| Q4 24 | $446.0M | $-159.0M | ||
| Q3 24 | $545.0M | $71.0M | ||
| Q2 24 | $6.0M | $49.0M | ||
| Q1 24 | $-248.0M | $116.0M |
| Q4 25 | 21.6% | -0.7% | ||
| Q3 25 | 5.2% | 1.1% | ||
| Q2 25 | 3.1% | 1.5% | ||
| Q1 25 | -6.0% | 2.4% | ||
| Q4 24 | 10.5% | -2.0% | ||
| Q3 24 | 12.6% | 0.9% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | -6.5% | 1.5% |
| Q4 25 | 3.0% | 0.2% | ||
| Q3 25 | 3.0% | 1.0% | ||
| Q2 25 | 2.3% | 0.7% | ||
| Q1 25 | 3.3% | 0.7% | ||
| Q4 24 | 3.1% | 0.6% | ||
| Q3 24 | 3.4% | 1.6% | ||
| Q2 24 | 2.3% | 1.0% | ||
| Q1 24 | 3.2% | 0.9% |
| Q4 25 | 2.41× | — | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
UNFI
| Natural Segment | $4.3B | 55% |
| Conventional Segment | $3.1B | 40% |
| Retail Segment | $560.0M | 7% |
